Search
for
Sort by
Research 241–270 of 1000+
- Signal Mining for Non-Bleeding Adverse Event in Novel Oral Anticoagulants: A Pharmacovigilance Study Based on the FAERS Database
- Hair and nail adverse events during treatment with target therapies for metastatic melanoma
- Air pollution and skin diseases: Adverse effects of airborne particulate matter on various skin diseases
- “Nail loss after teriflunomide treatment: A new potential adverse event”
- FDA Reports of Alopecia as an Adverse Event to Isotretinoin
- Pilot Evaluation of the Efficacy and Safety of Xtressé™ Gummy-Based Nutraceutical Supplement in Women with Hair Loss
- Safety and Efficacy of an Oral Nutraceutical Supplement Gummy and Peptide Serum in Promoting Hair Growth: Initial Results of A Randomized Placebo Controlled Trial with an Open Label Extension
- Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 years of Age With Severe Alopecia Areata
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- Characterizing Lipid Changes and Use of Lipid-Lowering Medications in Patients With Alopecia Areata Treated With Baricitinib: Integrated Results From the BRAVE-AA1 and -AA2 Clinical Trials
- Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
- Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
- Suicidal behaviors (suicidal ideation, suicide attempt and completed suicide) in patients treated with finasteride for hair loss: Results from the U.S. FDA Adverse Event Reporting System (FAERS) database
- Spontaneous cutaneous adverse drug reaction reports—An analysis of a 10‐year dataset in Singapore
- Chemotherapy and the Skin: Understanding Dermatologic Side Effects
- Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects
- Management of Serious Adverse Events Following Deoxycholic Acid Injection for Submental and Jowl Fat Reduction: A Systematic Review and Management Recommendations
- Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
- Recent advances in understanding of radiation-induced skin tissue reactions with respect to acute tissue injury and late adverse effect
- Semaglutide and the Skin: An Overview of Current Evidence
- Cyclosporine-induced alopecia:a case report, FDA adverse event reporting system analysis and literature assessment
- Adverse Cutaneous Reactions to Antidepressants
- A Gender Hypothesis of sex disparities in adverse drug events
- Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
- Children and Adolescents with Alopecia Areata: Psychiatric Symptomatology and Life Events: A longitudinal case-control study: Before and During the COVID-19
- Adverse Drug Reactions in HIV/AIDS Patients on Highly Active Antiretro Viral Therapy: A Review of Prevalence
- Adverse Events Associated with Azathioprine Treatment in Korean Pediatric Inflammatory Bowel Disease Patients
- Adverse Dermatologic Effects of Cardiovascular Drug Therapy: Part III
- Survey on adverse events associated with drug therapy for breast cancer patients